Targets featured in this dataset:
The anti-mesothelin oncology landscape in one free database: 56 preclinical and clinical programs targeting MSLN, across CAR-T cells, ADCs, bispecific and trispecific antibodies, TCR-T cells, immunotoxins and cancer vaccines — mapped by developer and clinical stage, spanning ovarian cancer, mesothelioma, pancreatic cancer, NSCLC, and endometrial cancer.
56 preclinical and clinical programs targeting MSLN
Mesothelin (MSLN) is a GPI-anchored glycoprotein produced as a precursor that is cleaved into a membrane-bound form and a secreted fragment, megakaryocyte-potentiating factor. In healthy tissue, its expression is largely restricted to the mesothelial cells lining the pleura, peritoneum and pericardium, yet it is overexpressed in mesothelioma, ovarian and pancreatic cancers and a share of lung adenocarcinomas, where its binding to CA125 (MUC16) has been linked to peritoneal spread. Two features shape drug design: MSLN is shed from the tumor surface, creating a soluble pool that can soak up therapeutic binders, and its mesothelial expression defines the main on-target, off-tumor risk.
With 56 programs, MSLN is a crowded solid-tumor target, and cell therapy dominates: 26 CAR-T cell programs, plus TCR-T and CAR-monocyte approaches, alongside ADCs, bispecific and trispecific T-cell engagers, immunotoxins, a radioconjugate and cancer vaccines. No program has progressed beyond Phase II, and 24 have been discontinued, including most first-generation antibodies, ADCs and immunotoxins. Newer designs target membrane-proximal epitopes that escape soluble MSLN, add logic gates or armoring to cell therapies, and pair MSLN with a second tumor antigen such as FOLR1, CDH3 or CLDN18.2. Ovarian cancer, mesothelioma, pancreatic cancer and NSCLC lead the indications.
Featured companies include:
A2 Biotherapeutics, AbbVie, Amgen, Arsenal Biosciences, Bayer, Bristol Myers Squibb, Fred Hutchinson Cancer Center, Genentech, Janssen, Legend Biotech, Memorial Sloan Kettering Cancer Center, National Cancer Institute, Pfizer, RemeGen, University of Pennsylvania, Zymeworks
Need to discover or validate new targets, test your compounds, or analytical support for a trial?
Contact us